Psoriasis

Physicians should be vigilant when managing patients with psoriasis and concurrent metabolic disorders, according to a new study.

Response rates were greater with deucravacitinib vs placebo or apremilast at 16 weeks in patients with moderate to severe scalp psoriasis, according to one study.

A topical therapy, PF-07038124 0.01%, administered once daily was more effective than the vehicle control in patients with atopic dermatitis (AD) and plaque psoriasis, a study finds.

The top psoriasis articles included topics on new therapies for the treatment of psoriasis in adults.

In this study, 52% of adult patients achieved the treat-to-target goal of 1% BSA or less within 3 months of incorporating tapinarof cream into their biologic regimen.

Most studies involving the treatment of psoriasis do not contain any images of patients, a review finds.

Investigators explored the genetic relationship between psoriatic disease and serum lipid levels.

Mona Shahriari, MD, assistant clinical professor of dermatology at Yale University and associate director of clinical trials at Central Connecticut Dermatology, discusses how dermatologists and clinicians can work towards increasing diversity and inclusion in treating patients with skin of color with plaque psoriasis.

Two posters presented at the 2023 Fall Clinical Dermatology Conference examined patient demographics, clinical characteristics, and outcomes in patients with plaque psoriasis treated with tapinarof cream.

Bimekizumab-bkzx (Bimzelx) is the first dual interleukin 17A (IL-17A) and interleukin 17F (IL-17F) inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7200 per syringe.

Depression symptoms are often underdiagnosed and undertreated in patients with psoriasis and psoriatic arthritis, contributing to a worsened quality of life (QOL). However, a recent study found that depression, functional impairment, and worsened QOL are related.

Two posters presented at the 2023 Fall Clinical Dermatology Conference assessed phase 4 study findings on tildrakizumab in patients with moderate to severe plaque psoriasis.

Posters presented at the 2023 Fall Clinical Dermatology Conference evaluated how label warnings may affect new treatment initiation and real-word switching patterns for patients starting risankizumab.

Mona Shahriari, MD, assistant clinical professor of dermatology at Yale University and associate director of clinical trials at Central Connecticut Dermatology, discusses unique challenges dermatologists face when treating patients with skin of color, who may present differently from White patients.

Two posters presented at the 2023 Fall Clinical Dermatology conference identified common patterns among patients with psoriasis (PsO) and psoriatic arthritis (PsA).

No genes were identified in psoriatic patches that were not also mutated in the patient’s unaffected skin area.

Mona Shahriari, MD, assistant clinical professor of dermatology at Yale University and associate director of clinical trials at Central Connecticut Dermatology, provides on overview of the treatment landscape in patients with skin of color with plaque psoriasis.

This study aimed to evaluate the association between the disease burden of psoriasis and the switching of systemic biologic therapies in patients with both psoriasis and psoriatic arthritis.

Psoriasis status from time of diagnosis to initiation of current treatment was less favorable for patients with mild psoriasis compared with moderate psoriasis, according to one study.

Compared with White patients, Black male patients had a higher prevalence of palmoplantar psoriasis, according to one study.

FDA action is no longer expected in Q3 of 2023.

Psoriasis increases the risk of cutaneous melanoma, according to the findings of a new study.

Decreased coronary flow was associated with severe psoriasis, according to one study.

Patients treated by rheumatologists were more often treated with tumor necrosis factor inhibitors, according to one study.

Telehealth visits were just as effective as in-person visits at managing patients initiating apremilast.

Lower fertility rate and increased risk of pregnancy loss were identified among women with moderate to severe psoriasis, according to a new study.

Patients and physicians often disagree on the patient’s disease severity, creating a relationship barrier and frustration among both parties.

The most severe psoriasis was associated with the lowest blood levels of vitamin D and the greatest affected body surface area.

No significant differences regarding racial backgrounds were found when measuring access to biologics among adult patients with psoriasis living in the United States, according to one study.

Survey responses revealed the rates and times at which patients switched from oral to biologic therapies.